Inhibition of ribonucleotide reductase by caracemide.
Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from rat Novikoff tumor. It was found to be an active inhibitor, about one-ninth as effective as hydroxyurea.